Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma

Bibliography

• Ascani S, Zinzani PL, Gherlinzoni F, Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 1997;8(6):583-92
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124-30
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103(7):2474-9
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107(1):265-76
   PubMed Web of Science ®Google Scholar
• Abouyabis AN, Shenoy PJ, Lechowicz MJ, Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49(11):2099-107
   PubMed Web of Science ®Google Scholar
• Malik SM, Liu K, Qiang X, Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2010;16(20):4921-7
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Gutierrez A, Martinez-Delgado B, Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. Crit Rev Oncol Hematol 2009;71(3):181-98
   PubMed Web of Science ®Google Scholar
• Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9(7):717-20
   PubMed Web of Science ®Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15(10):1467-75
   PubMed Web of Science ®Google Scholar
• Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004;15(10):1447-9
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Aoun P, Wu D, Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93(11):3913-21
   PubMed Web of Science ®Google Scholar
• Jillella AP, Murren JR, Hamid KK, P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. Cancer Invest 2000;18(7):609-13
   PubMed Web of Science ®Google Scholar
• Campo E, Gaulard P, Zucca E, Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol 1998;9(8):835-43
   PubMed Web of Science ®Google Scholar
• Chen AI, Advani RH. Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. J Natl Compr Canc Netw 2008;6(4):428-35
   PubMedGoogle Scholar
• Schmitz N, Trumper L, Ziepert M, Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116(18):3418-25
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134(2):202-7
   PubMed Web of Science ®Google Scholar
• Chen AI, McMillan A, Negrin RS, Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant 2008;14(7):741-7
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001;113(1):185-7
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006;58(1):35-9
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148(2):256-67
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103(8):2920-4
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28(11):1870-7
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(27):4293-7
   PubMed Web of Science ®Google Scholar
• Dueck G, Chua N, Prasad A, Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116(19):4541-8
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Hamlin PA, Portlock C, Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007;139(3):425-8
   PubMed Web of Science ®Google Scholar
• Wang ES, O'Connor O, She Y, Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 2003;44(6):1027-35
   PubMed Web of Science ®Google Scholar
• Hafler JP, Connors KM, Volkan K, Developing and evaluating a residents' curriculum. Med Teach 2005;27(3):276-82
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Colwell WT, A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998;42(4):313-18
   PubMed Web of Science ®Google Scholar
• Mould DR, Sweeney K, Duffull SB, A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma. Clin Pharmacol Ther 2009;86(2):190-6
   PubMed Web of Science ®Google Scholar
• StatBite: FDA oncology drug product approval in 2009. J Natl Cancer Inst 2010;102(4):219
   PubMedGoogle Scholar
• DeGraw JI, Colwell WT, Piper JR, Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 1993;36(15):2228-31
   PubMed Web of Science ®Google Scholar
• Toner LE, Vrhovac R, Smith EA, The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma. Clin Cancer Res 2006;12(3):924-32
   PubMed Web of Science ®Google Scholar
• Krug LM, Ng KK, Kris MG, Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 2000;6(9):3493-8
   PubMed Web of Science ®Google Scholar
• Venitz J, Brar S, Pronk GJ, Pralatrexate pharmacokinetics with intravenous administration to oncology patients [poster abstract B211]. Mol Cancer Ther 2009;27(26):4357-64
   Google Scholar
• Allos Therapeutics I. FOLOTYN(R) US Prescribing Information/Patient Package Insert Rev. 3. Folotyn (pralatrexate) [Package Insert]. Allos Therapeutics, Inc; Westminster, CO; 2011
   Google Scholar
• O'Connor OA, Horwitz S, Hamlin P, Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009;27(26):4357-64
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, DeGraw JI, Moccio DM, New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 1984;12(1):18-25
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ [Accessed 2012 January 3 2013]
   Google Scholar
• O'Connor OA, Pro B, Pinter-Brown L, Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29(9):1182-9
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17(4):1244
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579-86. 11
   PubMed Web of Science ®Google Scholar
• Shustov AR BPS, Horwitz SM, Jacobsen ED, Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): relationship between response and survival. J Clin Oncol 2010;28(15s Suppl):abstract 8054
   Google Scholar
• Popplewell L PB, Jacobsen E, Horwitz SM, Stem cell transplant (SCT) and pralatrexate therapy: outcome of patients with relapsed or refractory peripheral T-cell lymphoma who received SCT prior to or following pralatrexate therapy [poster abstract]. Blood 2009; (Proceedings of the 51st annual American Society of Hematology (ASH), New Orleans, LA, 668, 5-8 December 2009):[abstract 3420]
   Google Scholar
• Piekarz RL, Frye R, Prince HM, Phase I trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117(22):5827-35
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, Analysis of patients with common peripheral T-Cell lymphoma subtypes from a phase 2 study of romidepsin in relapsed or refractory T-cell lymphoma. ASH Ann Meet Abstr 2011;118(21):abstract 591
   Google Scholar
• Jain S, Jirau-Serrano X, Palermo FC, Novel Imaging Modalities in Innovative Xenograft Mouse Model of T-Cell Lymphoma Confirm Marked Syndergy of Romidepsin and Pralatrexate [abstract 2758]. ASH Annual Meeting Abstract; 2012
   Google Scholar
• Hecht TT, Longo DL, Cossman J, Production and characterization of a monocloncal antibody that binds Reed-Sternberg cells. J Immunol 1985;134(6):4231-6
   PubMed Web of Science ®Google Scholar
• Younes A, Consoli U, Snell V, CD 30 ligand in lymphoma patients with CD30+ tumors. J Clin Oncol 1997;15(11):3355-62
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger DD, Anderson JR, Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13(1):140-9
   PubMed Web of Science ®Google Scholar
• Went P, Agostinelli C, Gallamini A, Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 2006;24(16):2472-9
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, Durable remission with brentuximab vedotin (SGN-35): updated results of phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 2011;29: [abstract 8032]
   PubMedGoogle Scholar
• Horwitz SM, Advani R, Sankhala K, Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: phase I results. Blood ASH Ann Meet 2009;114:abstract 1678
   Google Scholar
• Willemze R, Jaffe ES, Burg G, WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105(10):3768-85
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119(18):4115-22
   PubMed Web of Science ®Google Scholar
• Kelly K, Azzoli CG, Zatloukal P, Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol 2012;7(6):1041-8
   PubMed Web of Science ®Google Scholar